Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
5 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Lancet. 2019 Jan 12;393(10167):143-155. doi: 10.1016/S0140-6736(18)32462-0. Epub 2018 Nov 9.
Lancet. 2019.
PMID: 30420123
Clinical Trial.
Psychiatric Symptoms in Patients Receiving Dolutegravir.
Fettiplace A, Stainsby C, Winston A, Givens N, Puccini S, Vannappagari V, Hsu R, Fusco J, Quercia R, Aboud M, Curtis L.
Fettiplace A, et al.
J Acquir Immune Defic Syndr. 2017 Apr 1;74(4):423-431. doi: 10.1097/QAI.0000000000001269.
J Acquir Immune Defic Syndr. 2017.
PMID: 27984559
Free PMC article.
Item in Clipboard
Liver toxicity in oncology trials and beyond: a simplified concept for management of hepatocellular drug-induced liver injury in patients with abnormal baseline liver tests.
Merz M, Fettiplace A, Marcinak J, Tillmann HL, Rockey DC, Kullak-Ublick GA.
Merz M, et al. Among authors: fettiplace a.
Expert Opin Drug Saf. 2024 Apr;23(4):527-537. doi: 10.1080/14740338.2024.2327509. Epub 2024 Apr 4.
Expert Opin Drug Saf. 2024.
PMID: 38482670
Item in Clipboard
A comprehensive analysis of liver safety across zibotentan oncology trials: knowledge of the past offers new perspectives on the present.
Fettiplace A, Matis-Mitchell S, Molodetskyi O, Söderbergh M, Oscarsson J, Lin M, Ravikiran S, Billger M, Ambery P.
Fettiplace A, et al.
Expert Opin Drug Saf. 2024 Apr;23(4):477-486. doi: 10.1080/14740338.2024.2328816. Epub 2024 Mar 24.
Expert Opin Drug Saf. 2024.
PMID: 38469902
Item in Clipboard
Consensus Guidelines: Best Practices for the Prevention, Detection and Management of Hepatitis B Virus Reactivation in Clinical Trials with Immunosuppressive/Immunomodulatory Therapy.
Cohen EB, Regev A, Garg A, Di Bisceglie AM, Lewis JH, Vierling JM, Hey-Hadavi J, Steplewski K, Fettiplace A, Chen CL, Pehlivanov N, Kendrick S, I Avigan M.
Cohen EB, et al. Among authors: fettiplace a.
Drug Saf. 2024 Apr;47(4):321-332. doi: 10.1007/s40264-024-01399-4. Epub 2024 Feb 14.
Drug Saf. 2024.
PMID: 38353882
Free PMC article.
Item in Clipboard
Cite
Cite